Test the Waters
Biosuperior Technology

Biosuperior Technology

Creating Life Saving Therapeutics For Serious Lung Disease

Security Type
Min Investment
Los Altos, CA
Offering Date
August 18, 2021

Company Description

BioSuperior Technology is excited to be developing therapeutics for the prevention and treatment of serious lung diseases such as Acute Respiratory Distress Syndrome (ARDS), including SARS-CoV-2 induced illness. Our lead candidate is also expected to treat illness resulting from other lung infections, and following severe smoke inhalation. These expectations are based on a strong understanding of lung biology and data from animal model studies.

Key Deal Facts

Our 1st treatment is for serious lung illness. It is designed to keep patients out of the ICU and prevent long-COVID.
Our drug candidate has worked in animal models. It saves over 50% of animals that have serious lung infection.
Our drug candidate is based on 20 years of scientific research.
We have been awarded $300k from the March of Dimes.
We have patents pertaining to our core technologies: US Patent 8,240,080, and, BioST-002.P2, filed October 16, 2020.
We are collaborating closely with Columbia University and National Jewish Health scientists.
Our team includes 4 scientists with about 100 years of cumulative industrial experience.
Collectively, we have authored 11 patents, 100 peer reviewed publications, and 7 book chapters.

Management Team / Advisory Board Bios

Russ Lehrman, CEO & President
30 yrs + in Pharmaceutical Research and Development. Russ has helped create new drugs for diabetes, Adult Macular Degeneration, and Multiple Sclerosis. He is an Advisor to the Stanford University SPARK Program and co-founder of 2 companies.

Lucia Mokres, VP of Clinical and Regulatory Affairs
Lucia was the Chief Medical Officer of EpiBiome. Prior to that, she Investigated the development of Chronic Lung Disease in premature infants using mouse models of lung development.

Ehud Goldin, VP of Biological Research
An expert biologist who has many cell research discoveries that have helped in the understanding of human health. Ehud has managed human clinical trials relevant to his research.
Amount Raised : $0
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.

Research Reports

No reports have been submitted

Become a Reporter